leisure time -WSS

leisure time

author：leisure time 2025-10-01 04:32:53 - browse：23

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： How to bring more disabled researchers into academia

WSS

How to bring more disabled researchers into academia

UnitedHealth quietly bought dozens of outpatient centers

CDC marks new Covid

Amylyx ALS drug failure raises questions and concerns

Readout Newsletter: The latest on Novavax, Merck, Bluebird

UnitedHealth quietly bought dozens of outpatient centers

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

knowledge

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Medical leaders decry Supreme Court decision on affirmative action

Reconstructing family trees of blood cells may help predict disease

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Virginia high school admissions case could be legal follow

10 reasons why health care startups fail

focus

A deep dive into Applied Therapeutics’ data, and questions on Cassava

RSV shot was 90% effective at preventing hospitalizations in kids

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Just how do doctors, lawmakers, and the public define abortion?

Vertex non

Change Healthcare cyberattack prompts Medicare loan program

leisure time

entertainment

hotspot

hotspot